OBJECTIVES: Introduction of next-generation targeted therapies, such as ibrutinib, a first-in-class Bruton’s tyrosine kinase inhibitor, for treatment of chronic lymphocytic leukemia (CLL) is expected to redefine the therapeutic landscape. In this study, we aimed to explore and benchmark recent trends in utilization of frontline systemic therapies for CLL in the United States (US).

METHODS: Using a population-level commercial claims database, this retrospective cohort study included patients (aged ≥18 years) initiating systemic therapy after the first CLL diagnosis during July 2012 through June 2016. Percentage of patients treated with first-line therapy regimens was assessed by calendar year and stratified by age group (<65 years and ≥65 years). All analyses were descriptive in nature.

RESULTS: CONCLUSIONS: This study demonstrates a substantial increase in the uptake of ibrutinib as the frontline therapy for CLL in the US. As novel agents are approved or included in the treatment guidelines for CLL (e.g. venetoclax, acalabrutinib), further research should evaluate post-2016 utilization trends overall and by therapy line.